Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press113610.17650/1726-9776-2007-3-4-36-40DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак предстательной железыCost-effectiveness of screening for prostate cancerЭкономическая эффективность скрининга рака предстательной железыKaprinA. D.КапринА. Д.
Russian Federation

Department of Health Care and Public Health Organization

Moscow

Кафедра организации здравоохранения и общественного здоровья РМАПО

г. Москва

NaigovzinaN. B.НайговзинаН. Б.
Russian Federation

Department of Health Care and Public Health Organization

Moscow

Кафедра организации здравоохранения и общественного здоровья РМАПО

г. Москва

IvanovS. A.ИвановС. А.
Russian Federation

Department of Health Care and Public Health Organization

Moscow

Кафедра организации здравоохранения и общественного здоровья РМАПО

г. Москва

BashmakovV. A.БашмаковВ. А.
Russian Federation

Department of Health Care and Public Health Organization

Moscow

Кафедра организации здравоохранения и общественного здоровья РМАПО

г. Москва

Russian Medical Academy of Postgraduate EducationРоссийская медицинская академия последипломного образованияRussian Radiology Research Center, Russian Agency for Health CareРоссийский научный центр рентгенорадиологии Росздрава301220073436401602202016022020https://oncourology.abvpress.ru/oncur/article/view/1136

The total expenses on the early detection and further treatment of prostate cancer (PC) were analyzed in 1785 males aged 40 to 70 years, examined at the Russian Radiology Research Center, for prostate pathology-unassociated diseases in 2000—2005. A control group comprised 734 patients referred to urologist of the Russian Radiology Research Center Polyclinic during the same period. In the study group, the cost of treatment per patient with detected PC was 60,150 rbl (including that of screening) while in the control group, it was 150,376 rbl. The expected economic effect of introduction of a PC screening program at the federal level may be as many as 8,970,066,799.48 rbl.

.

1. Харченко В.П., Гафанов Р.А., Каприн А.Д. Гормонорезистентный рак предстательной железы. Возможности лечения: Обзор. Андрол и генитал хир 2001;(4):8—12.Харченко В.П., Гафанов Р.А., Каприн А.Д. Гормонорезистентный рак предстательной железы. Возможности лечения: Обзор. Андрол и генитал хир 2001;(4):8—12.2. Корчагин В.П., Найговзина Н.Б. Организационно-экономические аспекты реализации концепции развития здравоохранения и медицинской науки в Российской Федерации. Экон здравоохр 1998;(8):12—6.Корчагин В.П., Найговзина Н.Б. Организационно-экономические аспекты реализации концепции развития здравоохранения и медицинской науки в Российской Федерации. Экон здравоохр 1998;(8):12—6.3. Postma R., Roobol M., Schroder F.H., van der Kwast T.H. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004;100:968—75.Postma R., Roobol M., Schroder F.H., van der Kwast T.H. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 2004;100:968—75.4. Holmberg H., Carlsson P., Lofman O., Varenhorst E. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden. Health Policy 1998;45(2):133—47.Holmberg H., Carlsson P., Lofman O., Varenhorst E. Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden. Health Policy 1998;45(2):133—47.5. Makinen T., Tammela T.L., Stenman U.H. et al. Second round results of the Finish population-based prostate cancer screening trial. Clin Cancer Res 2004;(10):2231—6.Makinen T., Tammela T.L., Stenman U.H. et al. Second round results of the Finish population-based prostate cancer screening trial. Clin Cancer Res 2004;(10):2231—6.6. Hugosson O., Aus G., Lilja H. et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397—405.Hugosson O., Aus G., Lilja H. et al. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004;100:1397—405.7. Roberts R.O. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999;161(2):529—33.Roberts R.O. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota. J Urol 1999;161(2):529—33.8. Albertsen P.C., Hanley J.A., Harlan L.C. et al. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: A population based analysis. J Urol 2000;163:1138.Albertsen P.C., Hanley J.A., Harlan L.C. et al. The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: A population based analysis. J Urol 2000;163:1138.